US2006165716A1PendingUtilityA1

Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae

55
Assignee: TELFORD JOHN LPriority: Jul 29, 2004Filed: Jul 29, 2005Published: Jul 27, 2006
Est. expiryJul 29, 2024(expired)· nominal 20-yr term from priority
Inventors:John TelfordGuido GrandiPeter LauerMarirosa MoraImmaculada Y RosDomenico MaioneGuiliano BensiDaniela RinaudoVega MasignaniMichelle BarocchiRino Rappuoli
C07K 16/1267A61P 37/04A61P 43/00A61K 39/09A61K 39/092A61P 31/04A61K 39/0208A61K 39/085A61K 39/095A61K 39/05A61K 2039/523A61K 39/08Y02A50/30
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to the identification of a new adhesin islands within the genomes of several Group A and Group B Streptococcus serotypes and isolates. The adhesin islands are thought to encode surface proteins which are important in the bacteria's virulence. Thus, the adhesin island proteins of the invention may be used in immunogenic compositions for prophylactic or therapeutic immunization against GAS or GBS infection. For example, the invention may include an immunogenic composition comprising one or more of the discovered adhesin island proteins.

Claims

exact text as granted — not AI-modified
1 . An immunogenic composition comprising a purified Group B  Streptococcus  (GBS) adhesin island (AI) polypeptide in oligomeric form.  
     
     
         2 . The immunogenic composition of  claim 1  wherein the GBS AI polypeptide is selected from a GBS AI-1.  
     
     
         3 . The immunogenic composition of  claim 1  wherein the GBS AI polypeptide is selected from a GBS AI-2.  
     
     
         4 . The immunogenic composition of  claim 2  wherein the GBS AI polypeptide is selected from the group consisting of GBS 80, GBS 104, GBS 52, and fragments thereof.  
     
     
         5 . The immunogenic composition of  claim 3  wherein the GBS AI polypeptide is selected from the group consisting of GBS 59, GBS 67, GBS 150, 01521, 01523, 01524, and fragments thereof.  
     
     
         6 . The immunogenic composition of  claim 4  wherein the GBS AI polypeptide is GBS 80.  
     
     
         7 . The immunogenic composition of any of claims  1 - 6  wherein the oligomeric form is a hyperoligomer.  
     
     
         8  ( 22 ). An immunogenic composition comprising a purified Gram positive bacteria adhesin island (AI) polypeptide in an oligomeric form.  
     
     
         9  ( 23 ). The immunogenic composition of  claim 8  wherein the Gram positive bacteria is of a genus selected from the group consisting of  Streptococcus, Enterococcus, Staphylococcus, Clostridium, Corynebacterium , or  Listeria.    
     
     
         10  ( 24 ). The immunogenic composition of  claim 9  wherein the Gram positive bacteria is of the genus  Streptococcus.    
     
     
         11  ( 35 ). The immunogenic composition of  claim 10  wherein the genus  Streptococcus  bacteria is Group A  Streptococcus  (GAS) bacteria and the Gram positive bacteria AI polypeptide is a GAS AI polypeptide.  
     
     
         12  ( 36 ). The immunogenic composition of  claim 11  wherein the GAS AI polypeptide is selected from a GAS AI-1.  
     
     
         13  ( 37 ). The immunogenic composition of  claim 11  wherein the GAS AI polypeptide is selected from a GAS AI-2.  
     
     
         14  ( 38 ). The immunogenic composition of  claim 11  wherein the GAS AI polypeptide is selected from a GAS AI-3.  
     
     
         15  ( 39 ). The immunogenic composition of  claim 11  wherein the GAS AI polypeptide is selected from a GAS AI-4.  
     
     
         16  ( 66 ). The immunogenic composition of any one of claims  8 - 15  wherein the oligomeric form is a hyperoligomer.  
     
     
         17 . An immunogenic composition comprising a first and a second Group B  Streptococcus  (GBS) adhesin island (AI) polypeptide.  
     
     
         18 . The immunogenic composition of  claim 17  wherein the first GBS AI polypeptide is encoded by a GBS AI-1.  
     
     
         19 . The immunogenic composition of  claim 18  wherein the second GBS AI polypeptide is encoded by a GBS AI-2.  
     
     
         20 . The immunogenic composition of  claim 18  wherein the first GBS AI polypeptide is selected from the group consisting of GBS 80, GBS 104, GBS 52, and fragments thereof.  
     
     
         21 . The immunogenic composition of  claim 19  wherein the second GBS AI polypeptide is selected from the group consisting of GBS 59, GBS 67, GBS 150, 01521, 01523, 01524, and fragments thereof, and wherein the first and the second GBS AI polypeptide are not the same polypeptide.  
     
     
         22 . The immunogenic composition of  claim 19  wherein the first GBS AI polypeptide is GBS 80 and the second GBS AI polypeptide is GBS 67.  
     
     
         23 . An immunogenic composition comprising a first and a second Gram positive bacteria adhesin island (AI) polypeptide.  
     
     
         24 . The immunogenic composition of  claim 23  wherein the Gram positive bacteria is  Streptococcus, Enterococcus, Staphylococcus, Clostridium, Corynebacterium , or  Listeria.    
     
     
         25 . The immunogenic composition of  claim 23  wherein the first Gram positive bacteria AI polypeptide is a first Group A  Streptococcus  (GAS) AI polypeptide.  
     
     
         26 . The immunogenic composition of  claim 25  wherein the first GAS AI polypeptide is a first GAS AI-1 polypeptide.  
     
     
         27 . The immunogenic composition of  claim 25  wherein the first GAS AI polypeptide is a first GAS AI-2 polypeptide.  
     
     
         28 . The immunogenic composition of  claim 25  wherein the first GAS AI polypeptide is a first GAS AI-3 polypeptide.  
     
     
         29 . The immunogenic composition of  claim 25  wherein the first GAS AI polypeptide is a first GAS AI-4 polypeptide.  
     
     
         30 . The immunogenic composition of any one of claims  25 - 29  wherein the second Gram positive bacteria AI polypeptide is a second GAS AI polypeptide.  
     
     
         31 . The immunogenic composition of  claim 30  wherein the second GAS AI polypeptide is a second GAS AI-1 polypeptide.  
     
     
         32 . The immunogenic composition of  claim 30  wherein the second GAS AI polypeptide is a second GAS AI-2 polypeptide.  
     
     
         33 . The immunogenic composition of  claim 30  wherein the second GAS AI polypeptide is a second GAS AI-3 polypeptide.  
     
     
         34 . The immunogenic composition of  claim 30  wherein the second GAS AI polypeptide is a second GAS AI-4 polypeptide.  
     
     
         35 . A modified Gram positive bacterium adapted to produce increased levels of AI surface protein.  
     
     
         36 . The modified Gram positive bacterium of  claim 35  wherein the AI surface protein is in oligomeric form.  
     
     
         37 . The modified Gram positive bacterium of  claim 36  wherein the oligomeric form is a hyperoligomer.  
     
     
         38 . The modified Gram positive bacterium of any one of claims  35 - 37  which is a non-pathogenic Gram positive bacterium.  
     
     
         39 . The modified Gram positive bacterium of  claim 38  wherein the non-pathogenic Gram positive bacterium is  Lactococcus  lactis.  
     
     
         40 . A method for manufacturing an oligomeric adhesin island (AI) surface antigen comprising: 
 culturing a Gram positive bacterium that expresses an oligomeric AI surface antigen and    isolating the expressed oligomeric AI surface antigen.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.